With new phase 3 data in hand, Boehringer Ingelheim is preparing to file for approval of nerandomilast, a would-be successor ...

For the past eight years, the CDD for Biologics Summit has united computational and structural biologists, along with protein ...

The European Society for Medical Oncology (ESMO) 2024 meeting was a well-attended affair at the sprawling Fira Gran Via ...

Unearthing novel targets for radiopharmaceuticals from ACP3m, AVB6, AVB8, and PDL-1 with Philochem, TRIMT, Fusion-AstraZeneca ...

Mid-stage data reported at the ESMO congress in Barcelona showed that ponsegromab was able to increase weight by 5.6% at the ...

The critical need to improve prior authorisation processes might have reached its tipping point on the 17th January. That’s ...

Finding oneself at an advanced stage of disease is devastating and may diminish one’s hope for the future. Participation in a ...

Apple has the FDA authorisation it needs to bring its software for detecting sleep apnoea to the Apple Watch, coinciding with ...

As a result, commercial teams are evolving as valuable partners to HCPs. From educating key experts before launch and ...

Johnson & Johnson is planning a phase 3 programme for Rybrevant in colorectal cancer as a follow-up to its first indication ...

AstraZeneca has revealed the data for Imfinzi in muscle-invasive bladder cancer (MIBC) that it hopes will be enough to secure ...